Halo is developing first-in-class, disease-modifying therapies for pulmonary hypertension and interstitial lung disease
Halo is exploiting novel insights in ECM biology by selectively modulating its components to address diseases with high unmet need that are driven by inflammation and fibrosis
We are building a differentiated pipeline based on novel insights into how dysregulation of the ECM drives disease.
Alterations to the ECM are associated with a variety of conditions including pulmonary hypertension, lung fibrosis, liver fibrosis, and diabetes.